Answers are grounded in this paper and cite their sources.
Observational analysis shows real-world efficacy of enfortumab vedotin in Japanese patients, indicating treatment potential for broader groups.
EV exhibited real-world efficacy in Japanese mUC patients comparable to the eligible patients' outcomes in the EV-301 trial. Ineligible patients showed statistically inferior outcomes.
No takes yet. Share an insight, caveat, or question.
Yajima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: